FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013916210> ?p ?o ?g. }

• W3013916210 endingPage "218" @default.
• W3013916210 startingPage "211" @default.
• W3013916210 abstract "Introduction Immune-related hepatitis (ir-hepatitis) is a common side-effect of checkpoint inhibitors (CPIs). Here, we characterise ir-hepatitis in a large cohort of patients with metastatic melanoma (MM) treated with CPIs and describe potential risk factors and efficacy of medical management. Methods The retrospective study included a large cohort of patients with MM treated with CPIs between 2010 and 2019. Patients were retrieved from the national Danish Metastatic Melanoma Database. Results Five hundred twenty one patients were included. Ir-hepatitis was found in 6.8% of patients. Combination therapy was associated with a significantly greater risk than monotherapy. Of all patients, 34.9% with hepatitis had a different hepatitis grading, when based on either alanine transaminase (ALT) or aspartate transaminase (AST) levels. Of all patients, 72.1% with hepatitis received steroid treatment, and two patients received additional second-line immunosuppressants. Of all patients, 35.5% experienced hepatitis relapse during steroid tapering. Of all patients, 18.6% and 25% of patients with grade ≥2 and ≥ III3, respectively, developed hepatitis within 7 days after finishing an antibiotic treatment for infection. Patients (62.5%) who received a cumulative dose of >4000 mg steroid experienced cancer progression, compared with 22.7% of patients treated with <4000 mg. Conclusion Several observations of clinical importance were made. Infection and antibiotic treatment during CPIs could be a possible risk factor for developing ir-hepatitis. Severity of ir-hepatitis is potentially underestimated in a significant number of patients, if only one liver enzyme is measured. The role of second-line immunosuppressants needs to be further investigated because of the high risk of hepatitis relapse during steroid tapering and the potential negative impact of cumulative steroid dose on response to CPIs." @default.
• W3013916210 created "2020-04-03" @default.
• W3013916210 creator A5013960209 @default.
• W3013916210 creator A5031370633 @default.
• W3013916210 creator A5051043977 @default.
• W3013916210 creator A5085145679 @default.
• W3013916210 date "2020-05-01" @default.
• W3013916210 modified "2023-10-02" @default.
• W3013916210 title "Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors" @default.
• W3013916210 cites W1973613923 @default.
• W3013916210 cites W2105057287 @default.
• W3013916210 cites W2109465910 @default.
• W3013916210 cites W2109653150 @default.
• W3013916210 cites W2151507811 @default.
• W3013916210 cites W2161550811 @default.
• W3013916210 cites W2179179825 @default.
• W3013916210 cites W2277326116 @default.
• W3013916210 cites W2490874882 @default.
• W3013916210 cites W2519279652 @default.
• W3013916210 cites W2550419061 @default.
• W3013916210 cites W2588698239 @default.
• W3013916210 cites W2736166064 @default.
• W3013916210 cites W2741316449 @default.
• W3013916210 cites W2749049242 @default.
• W3013916210 cites W2768429453 @default.
• W3013916210 cites W2786816161 @default.
• W3013916210 cites W2794538118 @default.
• W3013916210 cites W2890671115 @default.
• W3013916210 cites W2891633409 @default.
• W3013916210 cites W2898845456 @default.
• W3013916210 cites W2899030278 @default.
• W3013916210 cites W2899231513 @default.
• W3013916210 cites W2907792173 @default.
• W3013916210 cites W2947435541 @default.
• W3013916210 doi "https://doi.org/10.1016/j.ejca.2020.02.041" @default.
• W3013916210 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32229418" @default.
• W3013916210 hasPublicationYear "2020" @default.
• W3013916210 type Work @default.
• W3013916210 sameAs 3013916210 @default.
• W3013916210 citedByCount "18" @default.
• W3013916210 countsByYear W30139162102020 @default.
• W3013916210 countsByYear W30139162102021 @default.
• W3013916210 countsByYear W30139162102022 @default.
• W3013916210 countsByYear W30139162102023 @default.
• W3013916210 crossrefType "journal-article" @default.
• W3013916210 hasAuthorship W3013916210A5013960209 @default.
• W3013916210 hasAuthorship W3013916210A5031370633 @default.
• W3013916210 hasAuthorship W3013916210A5051043977 @default.
• W3013916210 hasAuthorship W3013916210A5085145679 @default.
• W3013916210 hasConcept C126322002 @default.
• W3013916210 hasConcept C143998085 @default.
• W3013916210 hasConcept C160160445 @default.
• W3013916210 hasConcept C167135981 @default.
• W3013916210 hasConcept C181199279 @default.
• W3013916210 hasConcept C185592680 @default.
• W3013916210 hasConcept C2775876817 @default.
• W3013916210 hasConcept C2776029263 @default.
• W3013916210 hasConcept C2776455275 @default.
• W3013916210 hasConcept C2777203481 @default.
• W3013916210 hasConcept C2778606649 @default.
• W3013916210 hasConcept C2779679107 @default.
• W3013916210 hasConcept C2780567839 @default.
• W3013916210 hasConcept C2780799908 @default.
• W3013916210 hasConcept C55493867 @default.
• W3013916210 hasConcept C71924100 @default.
• W3013916210 hasConcept C90924648 @default.
• W3013916210 hasConceptScore W3013916210C126322002 @default.
• W3013916210 hasConceptScore W3013916210C143998085 @default.
• W3013916210 hasConceptScore W3013916210C160160445 @default.
• W3013916210 hasConceptScore W3013916210C167135981 @default.
• W3013916210 hasConceptScore W3013916210C181199279 @default.
• W3013916210 hasConceptScore W3013916210C185592680 @default.
• W3013916210 hasConceptScore W3013916210C2775876817 @default.
• W3013916210 hasConceptScore W3013916210C2776029263 @default.
• W3013916210 hasConceptScore W3013916210C2776455275 @default.
• W3013916210 hasConceptScore W3013916210C2777203481 @default.
• W3013916210 hasConceptScore W3013916210C2778606649 @default.
• W3013916210 hasConceptScore W3013916210C2779679107 @default.
• W3013916210 hasConceptScore W3013916210C2780567839 @default.
• W3013916210 hasConceptScore W3013916210C2780799908 @default.
• W3013916210 hasConceptScore W3013916210C55493867 @default.
• W3013916210 hasConceptScore W3013916210C71924100 @default.
• W3013916210 hasConceptScore W3013916210C90924648 @default.
• W3013916210 hasLocation W30139162101 @default.
• W3013916210 hasLocation W30139162102 @default.
• W3013916210 hasOpenAccess W3013916210 @default.
• W3013916210 hasPrimaryLocation W30139162101 @default.
• W3013916210 hasRelatedWork W1832604137 @default.
• W3013916210 hasRelatedWork W2357537422 @default.
• W3013916210 hasRelatedWork W2745950292 @default.
• W3013916210 hasRelatedWork W2995695343 @default.
• W3013916210 hasRelatedWork W3013916210 @default.
• W3013916210 hasRelatedWork W307921490 @default.
• W3013916210 hasRelatedWork W3204657062 @default.
• W3013916210 hasRelatedWork W4255223509 @default.
• W3013916210 hasRelatedWork W4317522875 @default.
• W3013916210 hasRelatedWork W1991288670 @default.
• W3013916210 hasVolume "130" @default.

• next